S2-E7.1 – The Newer Diabetes Drugs and NASH: Modes of Action

Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH

The group consider scientific issues surrounding the newer diabetes drugs. First, Jörn Schattenberg presented mode of action and research data on the two classes of drugs. After this, Wayne Eskridge asked questions from the patient perspective, Louise Campbell explores issues from a holistic perspective and Roger Green raised data points and concepts that arose in earlier episodes of the podcast.